Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. (NASDAQ: MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer, and its news flow reflects both scientific progress and commercial execution. Company updates frequently highlight developments around its flagship colorectal cancer screening test, ColoAlert, and its pancreatic cancer screening program, including PancAlert and related biomarker studies.
Investors and observers following MYNZ news can expect announcements on regulatory milestones, such as registrations and approvals that enable ColoAlert to be marketed in additional countries, as well as commercial partnerships with diagnostic laboratories, distributors, and digital health platforms. Examples include agreements to launch ColoAlert in Switzerland through a local laboratory partner, collaborations to introduce the test in South America, and inclusion of ColoAlert in digital preventive healthcare offerings in Germany.
News items also cover Mainz Biomed’s clinical development activities. These include updates on the eAArly DETECT and eAArly DETECT 2 studies for next generation colorectal cancer testing, presentations of clinical data on RNA‑based screening at international meetings, and feasibility and verification studies for blood‑based pancreatic cancer screening using licensed mRNA biomarkers and AI‑assisted algorithms. The company regularly announces participation in major conferences such as the American Association for Cancer Research Annual Meeting, MEDICA, and colorectal cancer screening committees organized by professional societies.
In addition, MYNZ news may include capital markets disclosures, such as securities purchase agreements, equity distribution arrangements, and summaries of financial reports filed on Form 6‑K. For readers seeking a consolidated view of these developments, this page provides a chronological feed of press releases and regulatory news that illustrate how Mainz Biomed is advancing its molecular diagnostic products, expanding market access, and managing its financing activities. Regular visits can help track scientific milestones, geographic expansion of ColoAlert, and progress in the company’s pancreatic cancer program.
Mainz Biomed (NASDAQ:MYNZ) has successfully regained full compliance with Nasdaq Capital Market listing requirements. The company received formal notice from Nasdaq on January 23, 2025, confirming its compliance with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1). This follows their previous confirmation of compliance with the minimum bid price requirement under Rule 5550(a)(2). As a result, MYNZ will maintain its listing and continue trading on the Nasdaq Capital Market.
Mainz Biomed (NASDAQ:MYNZ) has launched eAArly DETECT 2, a U.S. feasibility study to evaluate its next-generation colorectal cancer (CRC) test. The study will assess the performance of the company's proprietary mRNA biomarkers, AI-developed algorithm, and FIT test across approximately 2,000 average-risk patients.
The study aims to validate previous promising results and is expected to complete enrollment in the second half of 2025, with topline results targeted for Q4 2025. Following this study, Mainz Biomed plans to finalize protocols for ReconAAsense, their U.S. pivotal study scheduled for 2026.
The next-generation test incorporates five novel gene expression biomarkers acquired from Sherbrooke University in 2022, designed to detect both advanced adenomas (precancerous polyps) and early-stage CRC with high accuracy.
Mainz Biomed (NASDAQ:MYNZ) has partnered with Quest Diagnostics to advance its colorectal cancer screening test. Quest will provide laboratory services for Mainz's ReconAAsense FDA study, which will involve approximately 15,000 subjects across 150 US sites. The agreement includes an option for Quest to obtain semi-exclusive rights for testing services pending FDA approval.
The company's ColoAlert test, utilizing PCR technology to analyze stool samples for cancer DNA, has demonstrated promising sensitivity in detecting colorectal cancer and advanced adenomas. This development targets a significant market opportunity, as about one-third of US residents aged 50-75 have never undergone colorectal cancer screening, representing a potential $4.0B+ market in the US.
Mainz Biomed (NASDAQ:MYNZ) has completed its previously announced follow-on offering, raising $8.0 million in gross proceeds. The offering consisted of 1,367,521 units priced at $5.85 per unit. Each unit includes one ordinary share (or prefunded warrant), one Class A warrant, and one Class B warrant to purchase ordinary shares.
The Class A warrants are exercisable at $5.85 per share with a five-year expiration, while Class B warrants, also exercisable at $5.85, will expire either 30 days after the eAArly Detect 2 study results or one year from issuance. Maxim Group served as the sole placement agent for this at-the-market offering under Nasdaq rules.
Mainz Biomed (NASDAQ:MYNZ) has announced the pricing of a follow-on offering expected to raise $8.0 million in gross proceeds. The offering consists of 1,367,521 units, each priced at $5.85 and including one ordinary share (or prefunded warrant), one Series A warrant, and one Series B warrant.
The Series A warrants will be exercisable at $5.85 per share with a five-year expiration, while Series B warrants, also exercisable at $5.85, will expire either 30 days after the eAArly Detect 2 study results or one year from issuance. Maxim Group is serving as the sole placement agent, with the offering expected to close around December 16, 2024.
Mainz Biomed (NASDAQ:MYNZ) announced a 1-for-40 reverse stock split effective December 3, 2024. The split will reduce outstanding shares from approximately 80.1 million to 2.0 million. This action aims to increase market price per share to comply with Nasdaq's continued listing requirements. The company received notice of non-compliance with Nasdaq's minimum bid price requirement of $1.00 and the $2,500,000 minimum stockholders' equity requirement. Following a staff determination letter, Mainz Biomed plans to request a hearing to stay any suspension or delisting action.
Mainz Biomed (NASDAQ:MYNZ) has announced a collaborative agreement with Thermo Fisher Scientific to jointly develop and potentially commercialize Mainz's Next Generation colorectal cancer screening product. The collaboration will utilize Thermo Fisher's technologies, instrumentation, and information translation systems to develop proprietary mRNA-based screening tests.
The partnership aims to enhance Mainz Biomed's non-invasive test that targets both early detection of colorectal cancer and precancerous lesions, particularly advanced adenomas. The development will take place at Mainz Biomed's laboratories in Mainz, Germany, focusing on creating a home collection colorectal screening tool with enhanced adenoma detection capabilities.
Mainz Biomed N.V. (NASDAQ:MYNZ) reported mid-year 2024 financial results and provided a corporate update. Key highlights include:
- Revenue increased 4% year-over-year
- Loss from operations decreased by 32%
- Presented groundbreaking results at DDW 2024 and ASCO 2024, showing high sensitivity for colorectal cancer (CRC) and advanced adenomas
- Improved ColoAlert® product with new DNA stabilizing buffer
- Expanded collaboration with Liquid Biosciences for pancreatic cancer detection
- Received FDA feedback on breakthrough device designation
- Announced strategic focus on three key initiatives for 2024-2025
The company aims to grow its ColoAlert® business in Europe, develop its next-generation CRC screening product, and conduct a 2,000-patient study (eAArly DETECT 2) in the U.S. Mainz Biomed also implemented cost reductions to streamline operations.
Mainz Biomed N.V. (NASDAQ:MYNZ) has reported increased demand for its enhanced ColoAlert product, launched in July 2024. The improved version of this colorectal cancer (CRC) screening test is being adopted by existing partners and attracting new ones across Europe and select international markets. GANZIMMUN Diagnostics, a leading German laboratory, will fully implement the enhanced ColoAlert by early next year.
The enhanced ColoAlert features a proprietary DNA stabilizing buffer and streamlined collection devices, reducing retesting needs and offering faster results in 2-3 days. GANZIMMUN will showcase ColoAlert at the 57th Medizinische Woche Baden-Baden, a medical congress focusing on complementary medicine, from October 30 to November 3, 2024. This event will promote Mainz Biomed's DNA-based CRC screening test to medical professionals and researchers interested in advanced diagnostic solutions.
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company, has released a statement highlighting its strategic plans for 2025. CEO Guido Baechler anticipates a transformative year with major growth and U.S. FDA trials for their innovative cancer diagnostic solutions. The company's mRNA-based next-generation CRC screening test has shown significant clinical success, with sensitivities exceeding 90% for colorectal cancer and 80% for advanced adenomas.
Mainz Biomed plans to submit comprehensive data to the FDA in 2025, aiming to penetrate the U.S. market. The company is also advancing a pipeline of diagnostic technologies, including PancAlert. Despite current stock price concerns, management remains focused on delivering key milestones and executing their strategy to unlock shareholder value.